CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes.
J-F
JF
Lesesve
M
M
Debouverie
M
M
Decarvalho Bittencourt
M-C
MC
Béné
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015672:Erythroid Precursor Cells / Q000187:drug effects*; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D039441:Integrin alpha4 / Q000276:immunology*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D039441:Integrin alpha4